Pancreatic Cancer Research

ResearcherInstituto de Salud Carlos IIIActive in the last 2 years

Enrique Aranda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5471-2842; OpenAlex author ID A5068189051. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 15

  1. NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metastatic Pancreatic Cancer. Co-author DOI 10.1002/mco2.70682↗
  2. Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance. Last author DOI 10.1016/j.critrevonc.2025.104807↗
  3. Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry. Last author DOI 10.1016/j.esmorw.2025.100116↗
  4. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. Co-author DOI 10.1016/j.ctrv.2024.102719↗
  5. Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer. Last author DOI 10.1056/evidoa2300144↗
  6. Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer. Last author DOI 10.1186/s13148-023-01535-4↗
  7. Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. Co-author DOI 10.1186/s40364-023-00528-y↗
  8. The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreat… Last author DOI 10.3390/cancers13061210↗
  9. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated … Co-author DOI 10.1016/j.ejca.2020.07.035↗
  10. Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer. Last author DOI 10.3390/cancers12071754↗
  11. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. Co-author DOI 10.1371/journal.pone.0194844↗
  12. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety … Last author DOI 10.1016/j.ejca.2016.12.032↗
  13. Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. Co-author DOI 10.1016/j.taap.2016.10.003↗
  14. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Last author DOI 10.1007/s12094-014-1177-7↗
  15. Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management: a guideline of the TTD group. Last author DOI 10.1007/s12094-012-0840-0↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marta Toledano‐Fonseca · 7 shared papers, 2020–2026 · strength 1.46
  2. Antonio Rodríguez‐Ariza · 7 shared papers, 2020–2026 · strength 1.46
  3. Maria Victoria García‐Ortiz · 6 shared papers, 2021–2026 · strength 1.35
  4. Pablo Cano-Ramírez · 3 shared papers, 2023–2026 · strength 0.73
  5. Elena Brozos-Vázquez · 2 shared papers, 2024–2025 · strength 0.50
  6. Rafael López‐López · 2 shared papers, 2024–2025 · strength 0.50
  7. Alfredo Carrato · 4 shared papers, 2014–2025 · strength 0.49
  8. Carmen Guillén‐Ponce · 5 shared papers, 2016–2024 · strength 0.45
  9. Roberto Pazo-Cid · 3 shared papers, 2017–2025 · strength 0.40
  10. Javier Gallego-Plazas · 5 shared papers, 2014–2024 · strength 0.39
  11. Teresa Mercade Macarulla · 2 shared papers, 2024–2025 · strength 0.35
  12. Manuel Benavides · 5 shared papers, 2014–2020 · strength 0.32
  13. Fernando Rivera · 3 shared papers, 2014–2024 · strength 0.26
  14. Berta Laquente · 2 shared papers, 2014–2025 · strength 0.22
  15. Carles Pericay · 2 shared papers, 2014–2024 · strength 0.21
  16. Andrés Jesús Muñoz Martín · 1 shared paper, 2025 · strength 0.18
  17. Ismael Ghanem · 1 shared paper, 2025 · strength 0.18
  18. Florian Castet · 1 shared paper, 2025 · strength 0.18
  19. Ana Fernández Montés · 1 shared paper, 2025 · strength 0.18
  20. Eva Martínez de Castro · 1 shared paper, 2025 · strength 0.18
  21. Antonio Irigoyen · 3 shared papers, 2016–2018 · strength 0.18
  22. Rocio García‐Carbonero · 1 shared paper, 2024 · strength 0.17
  23. Carolina Torres · 2 shared papers, 2016–2018 · strength 0.13
  24. Jose Carlos Prados · 2 shared papers, 2016–2018 · strength 0.13
  25. Octavio Caba · 2 shared papers, 2016–2018 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.